Discrepancies Between BMI and Classic Cardiovascular Risk Factors

Obesity has been associated to a higher prevalence of comorbidities, such as insulin resistance, type 2 diabetes mellitus (T2DM), hypertension (HT), and dyslipidemia [1, 2]. The risk for these obesity-related comorbidities is elevated with increasing body mass index (BMI), at least up to a BMI of 40 kg/m² [1]. Additionally, the excess body weight in obesity is known to increase all-cause mortality as well as cardiovascular mortality [2, 3], with the lowest mortality rates in subjects with a BMI between 20 and 25 kg/m² [2, 4]. An increase in BMI of 5 kg/m² can increase all-cause mortality with 30%, as well as mortality as a result of ischemic heart disease, stroke, and T2DM [2].

Although obesity may be an independent risk factor for cardiovascular disease (CVD), different studies attribute this effect of obesity mainly to differences in classic cardiovascular risk (CVR) factors between non-obese and obese subjects instead to obesity itself [5, 6]. Classic CVR factors are widely used to estimate the risk of CVD or mortality and include systolic and diastolic blood pressure, glycated hemoglobin (HbA1c), and dyslipidemia [7], and the values of these classic CVR factors increase with increasing BMI. More recently, interest has increased in inflammation as a risk factor for CVD [8], using C-reactive protein (CRP) and complement component C3 (C3) as markers of inflammation. Both CRP and C3 are associated with an increased risk of CVD [9‐11] and increase with increasing BMI [12, 13].

In these studies, there has been an underrepresentation of morbidly obese subjects. Only few studies investigated the relationships of BMI and markers of dyslipidemia in morbid obesity, and these studies suggest an “obesity paradox” in which LDL-C levels are actually lower in subjects with the highest BMI, when compared to moderately obese subjects [14, 15], but these studies only focused on markers of dyslipidemia and not on other CVR factors.

The purpose of this study was to investigate the relationship of BMI with classic CVR factors and markers of inflammation in obese and non-obese subjects covering a wide range of BMI.

The obese group consisted of 576 subjects (418 women and 158 men), with a mean age of 44.2 (± 13.0) years and a mean BMI of 43.8 (± 7.6) kg/m². The non-obese group consisted of 377 subjects (173 women and 204 men). The mean age was 58.7 (± 13.0) years and the mean BMI was 25.0 (± 2.81) kg/m². Additional baseline characteristics of both groups are displayed in Table 1. The obese group included significantly more women than the non-obese group and was significantly younger. T2DM, HT, and current smoking behavior were more prevalent in the obese group. The obese group had a significantly higher BMI and waist circumference, when compared to the non-obese subjects. Focusing on classic cardiovascular risk factors, the mean systolic and diastolic blood pressure, LDL-C, and glucose levels were significantly higher in the obese subjects then those in non-obese subjects, while HDL-C was lower in the obese group. ApoB, C3, and CRP, which are thought to be related to cardiovascular risk, were also elevated in the obese subjects. Only total cholesterol levels and triglyceride levels were not different between the groups (Table 1).

In both the obese and non-obese group, no clear relation was observed between the level of BMI and the level of systolic blood pressure. In contrast, diastolic blood pressure increased with increasing BMI in the non-obese group, but no relation was observed between the level of diastolic blood pressure and BMI in the obese group. A similar trend was observed in the level of LDL-C and apoB in relation to BMI in both groups.

HDL-C decreased with increasing BMI in both groups, although the decrease in the obese group stabilizes from the second quintile and up. The significant decrease can be solely explained by a relatively high HDL-C level in the first BMI quintile of the obese group. In contrast to all other classic cardiovascular risk factors, the triglyceride level showed a gradual increase with increasing BMI in the non-obese group, but a gradual decrease in the obese group (Tables 2 and 3).

Inflammatory markers, which are also related to cardiovascular risk, followed a different pattern with BMI in both groups. Both CRP and leukocyte count were not related to BMI in the non-obese group. However, both parameters showed a clear relationship with BMI in the obese group. Complement C3 was the only parameter with a positive relationship with BMI in both the obese and non-obese groups (Tables 2 and 3).

Although diastolic and systolic blood pressure and the levels of LDL-C, glucose, and apoB were significantly increased in our obese subjects, the level of BMI in this group did not seem to influence the level of CVR factors. Therefore, derangement of CVR factors overall appears to reach a plateau at a certain level of obesity. A clear explanation for these observations is lacking.

One explanation for this finding may be the different metabolic effects of visceral and subcutaneous adipose tissue. Central adiposity is strongly associated with metabolic disturbances, such as insulin resistance, dyslipidemia, and systemic inflammation, which play essential roles in the pathogenesis of CVD [20, 21]. Furthermore, it is also associated with both cardiovascular mortality, cancer mortality, and overall mortality [20]. More specifically, fat distribution may play an important role in the risk of metabolic disease and CVD [22], in which visceral adipose tissue is most strongly related to measures of metabolic disease [21]. The present study suggests that visceral adipose tissue appears to have limited potential for expansion. Therefore, it can be hypothesized that after saturation of the visceral adipose tissue depot, further increases in obesity, e.g., BMI, result in fat storage in other depots, such as subcutaneous adipose tissue. As a result, the detrimental effects of visceral adipose tissue will not increase with increasing BMI in morbid and superobese subjects, as suggested by the present data. Expansion of subcutaneous adipose tissue at the expense of visceral adipose tissue may protect obese subjects from further deterioration of their CVR factors. The “adipose tissue expandability model” states that adipose tissue in general has a maximum potential for expansion in a given individual [23]. Once this degree of maximal expansion is reached, the adipose tissue is no longer able to safely store excess energy and the lipid flux to non-adipose organs will increase, resulting in ectopic fat accumulation. Storage of lipids in ectopic sites, such as hepatocytes or beta cells, can eventually result in metabolic disturbances as seen in obese patients [24, 25]. However, none of these studies evaluated the expansion capacity of visceral and subcutaneous adipose tissue in the course of increasing obesity in humans. It should be noted that a limitation of the present study is the small number of abdominal CT scans in the obese group. Furthermore, due to the lack of abdominal CT scans in the non-obese group, our data concerning the different adipose tissue depots only apply to obese subjects. Future studies investigating this issue should include measurements of adipose tissue depots.

In contrast to the previously mentioned CVR factors, inflammatory markers showed a clear relationship with the level of obesity in the obese group, while CRP and leukocyte count did not show an association with BMI in the non-obese group. Adipose tissue is known to secrete several adipokines that in part may cause increases in CRP as suggested by the relationship found in obese subjects between BMI and CRP. We did not use a high-sensitive CRP assay, which may in part explain the lack of association in the non-obese subjects. However, the inflammatory marker C3 did increase with increasing BMI in both the non-obese and obese groups, and C3 levels have been shown to be associated with CRP levels [26]. Although systemic inflammation is positively related to BMI, classical CVR factors seem to reach a maximal level at BMI 35–40 kg/m². Increased cardiovascular risk in subjects with BMI > 40 kg/m² may depend more on systemic inflammation and less so on classic CVR factors.

One unexpected finding of this study was the paradoxical decrease in TG with increasing BMI in our obese subjects, causing a peak level of TG within the group of subjects with a BMI between 26 and 35 kg/m². A limitation in our measurement of TG is that fasting venipuncture was not a requirement within our cohort; we were unable to distinguish between fasting and non-fasting subjects. However, the latest guidelines on lipid measurements question the need for fasting measurements since normal food intake does not largely affect lipid levels and the intra-individual variability in TG remains comparable throughout the day [27, 28]. Additionally, it is unlikely that non-fasting TG levels were mainly measured in subjects with a BMI between 26 and 35 kg/m². Therefore, we assume that the combination of fasting and non-fasting TG levels cannot explain the paradoxical trend in TG levels in the obese group. Porter et al. [29] previously noticed an increase of TG levels with increasing visceral fat volume. However, in the group with the highest visceral fat volumes, TG levels decreased with increasing subcutaneous fat volumes [29], which is in line with our findings. They suggested that subcutaneous adipose tissue may have beneficial effects on triglyceride metabolism in those subjects with large visceral adipose tissue volumes. Unfortunately, the molecular mechanism behind these findings has not been determined yet.

Even though excess body weight is known to increase all-cause mortality and cardiovascular mortality, previous studies only included subjects with a BMI up to 35 kg/m² [5, 20, 22]. However, 1.5 to 6% of all adults in developed countries are known to be morbidly obese [30], with a BMI of > 40 kg/m², and this prevalence is still rising. Much interest exists on the treatment of these morbidly obese subjects, in order to achieve significant weight loss and resolution of obesity-related comorbidity and thereby prevention of preterm mortality. The Prospective Studies Collaboration has demonstrated that overall mortality, as well as cardiovascular mortality, increases with increasing BMI, at least up to a BMI of 50 kg/m² [2]. Furthermore, overweight and obesity are associated with an early onset of CVD, not only resulting in higher mortality, but also in a greater portion of lives lived with CVD morbidity [31]. These findings should urge clinicians to intensify cardiovascular risk management in obese subjects. The current cardiovascular risk management should not be simply assumed to be suitable for morbidly obese patients. Previous studies reveal that hypertension in obese patients is of a different phenotype than hypertension in the lean population. In addition, not all antihypertensive drugs appear to be equally effective in obesity-related hypertension as in hypertension in lean patients [32, 33]. Furthermore, current guidelines for the treatment of dyslipidemia may not be suitable in obesity. Obese subjects are thought to require more intensive treatment for dyslipidemia with higher doses of lipid-lowering drugs [34]. Nevertheless, our data suggest that classic CVR factors do not further deteriorate with increasing BMI, from a BMI of approximately 35 kg/m² and higher. This suggests that the increased cardiovascular mortality in obesity is not caused by deterioration of classic cardiovascular risk factors, but that obesity is an independent cardiovascular risk factor itself. The increased cardiovascular mortality in obese patients [2, 35] may be influenced by other factors, such as systemic inflammation or non-atherosclerotic heart disease. Future studies should distinguish between different cardiovascular mortality causes in morbidly obese subjects, such as atherosclerotic heart disease, hypertensive heart disease, cardiomyopathies, or heart failure [36].

The distinct difference in baseline characteristics between the non-obese and obese groups in this study is a major limitation, even though the results were adjusted for comorbidity. When interpreting our results, we should keep in mind that patients on antihypertensive or lipid-lowering drugs were excluded from the analysis when the drug would interfere with the cardiovascular risk factor under investigation. Therefore, the relationships may not be applicable in subjects who already receive treatment for cardiovascular risk reduction. These excluded subjects could elevate the level of the specific risk factor if they were added to the analysis after cessation of their therapy. However, we do not have these data and felt that the use of antihypertensive and lipid-lowering drugs would disturb the natural relationship between BMI and the risk factors. Therefore, these confounding factors were excluded with the realization that the data may be biased. Regardless of this limitation, the results of this study provide new insights in cardiovascular risk in a population of high interest, since obesity and morbid obesity are reaching epidemic proportions [37] with substantial economic burden, not only in terms of medical costs, but also in terms of non-medical costs (e.g., absenteeism and personal costs) [38]. Our future perspective is to analyze cardiovascular risk factors in relation to BMI in a larger population in which we are able to match on age and gender and correct for confounding factors. The level of obesity should become a part of the currently available cardiovascular risk calculators.

In conclusion, obesity is related to an increased risk on metabolic and CVD and mortality, but this increased risk may not be solely explained by deterioration of classic CVR factors. The lack of correlation of CVR factors and BMI in obese subjects may be explained by the expansion of subcutaneous adipose tissue with increasing BMI after saturation of the visceral adipose tissue compartment. In order to reduce the risk of CVD and mortality in obese subjects, treatment may need to focus on reduction of systemic inflammation and on non-atherosclerotic heart diseases.